GLPwatch
In patients with HFpEF and obesity, semaglutide increased weight loss and reduced symptoms and physical limitations at 52 wk.
Ann Intern Med · 2023
Last updated 2026-05-28In a 52-week study of 529 adults with heart failure with preserved ejection fraction (HFpEF) and obesity, those taking semaglutide lost an average of 13.3% of their body weight compared to 2.6% with a placebo. Semaglutide also reduced symptoms like shortness of breath and fatigue, and improved physical limitations more than the placebo.
AI summary of the abstract below.
| Journal | Ann Intern Med, 2023 |
|---|---|
| Citations | 4 |
| Relative citation ratio | 0.38 |
| NIH percentile | 23 |
| Molecules | semaglutide |
| Conditions studied | Heart Failure, Obesity |
Abstract
Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al; STEP-HFpEF Trial Committees and Investigators. N Engl J Med. 2023;389:1069-1084. 37622681.
Verbatim abstract via PubMed 38048584 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.